Academic Journal
Near‐infrared photoimmunotherapy in the models of hepatocellular carcinomas using cetuximab‐IR700
| العنوان: | Near‐infrared photoimmunotherapy in the models of hepatocellular carcinomas using cetuximab‐IR700 |
|---|---|
| المؤلفون: | Takao, Seiichiro, Fukushima, Hiroshi, King, A. Paden, Kato, Takuya, Furusawa, Aki, Okuyama, Shuhei, Kano, Makoto, Choyke, Peter L., Escorcia, Freddy E., Kobayashi, Hisataka |
| المساهمون: | National Cancer Institute |
| المصدر: | Cancer Science ; volume 114, issue 12, page 4654-4663 ; ISSN 1347-9032 1349-7006 |
| بيانات النشر: | Wiley |
| سنة النشر: | 2023 |
| المجموعة: | Wiley Online Library (Open Access Articles via Crossref) |
| الوصف: | Epidermal growth factor receptor (EGFR) has emerged as an important therapeutic target in many cancers, and overexpression of EGFR is frequently observed in hepatocellular carcinomas (HCCs). Near‐infrared photoimmunotherapy (NIR‐PIT) is a new anticancer treatment that selectively damages the cell membrane of cancer cells after NIR light‐induced photochemical reaction of IR700, which is bound to a targeting antibody on the cell membrane. NIR‐PIT using cetuximab‐IR700 has already been approved in Japan, is under review by the US Food and Drug Administration (FDA) for advanced head and neck cancers, and its safety has been established. However, EGFR has not been investigated as a target in NIR‐PIT in HCCs. Here, we investigate the application of NIR‐PIT using cetuximab‐IR700 to HCCs using xenograft mouse models of EGFR‐expressing HCC cell lines, Hep3B, HuH‐7, and SNU‐449. In vitro NIR‐PIT using EGFR‐targeted cetuximab‐IR700 killed cells in a NIR light dose‐dependent manner. In vivo NIR‐PIT resulted in a delayed growth compared with untreated controls. In addition, in vivo NIR‐PIT in both models showed histological signs of cancer cell damage, such as cytoplasmic vacuolation and nuclear dysmorphism. A significant decrease in Ki‐67 positivity was also observed after NIR‐PIT, indicating decreased cancer cell proliferation. This study suggests that NIR‐PIT using cetuximab‐IR700 has potential for the treatment of EGFR‐expressing HCCs. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1111/cas.15965 |
| الاتاحة: | http://dx.doi.org/10.1111/cas.15965 https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.15965 |
| Rights: | http://creativecommons.org/licenses/by-nc/4.0/ |
| رقم الانضمام: | edsbas.8ABEFF36 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1111/cas.15965 |
|---|